サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1625427

CAR-T細胞療法市場、規模、シェア、動向、産業分析レポート：適応症別、標的抗原別、地域別 - 市場予測、2025年～2034年

CAR-T Cell Therapy Market Size, Share, Trends, Industry Analysis Report: By Indication, Target Antigen, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034

出版日
ページ情報
英文 116 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.84円
CAR-T細胞療法市場、規模、シェア、動向、産業分析レポート：適応症別、標的抗原別、地域別 - 市場予測、2025年～2034年
出版日: 2024年12月01日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Researchの最新調査によると、世界のCAR-T細胞療法市場規模は2034年までに1,888億4,000万米ドルに達する見込みです。本レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

キメラ抗原受容体T細胞（CAR-T）療法は、がん治療の進歩を象徴し、免疫腫瘍学を一変させました。この治療は、特定のがん抗原を標的とする合成レセプターを発現するように患者のT細胞を操作することで、特定のがん、特に血液悪性腫瘍に対して個別化された非常に効果的な治療オプションを提供します。世界のCAR-T細胞療法市場は、バイオテクノロジーの急速な進歩、CAR-T療法の承認率の上昇、革新的ながん治療に対する需要の高まりなどを背景に、過去10年間で急激な成長を遂げてきました。

世界のがん罹患率の増加と精密医療への選好の高まりが、CAR-T細胞療法のような先進的治療法への需要を煽っています。さらに、支持的な規制の枠組みと迅速な承認経路が、CAR-T療法の利用可能性を加速させています。政府および民間の研究投資は、CAR-T細胞療法市場の拡大をさらに後押ししています。

マルチターゲットCAR-T細胞やアーマードCAR-T細胞を含む次世代CAR-T療法の開発が、CAR-T細胞療法市場の成長を促進しています。マルチターゲットCAR-T細胞は複数の抗原を認識するように設計されており、従来のCAR-T治療の有効性を制限していた腫瘍の不均一性や抗原逃避などの問題に対処します。武装化CAR-T細胞は、サイトカインやその他の分子を分泌して抗腫瘍活性を高めることにより、免疫抑制的な腫瘍微小環境を克服するように設計されています。

CAR-T療法の応用は腫瘍学以外にも広がっています。研究者たちは、ループスや多発性硬化症などの自己免疫疾患や、HIVなどの感染症の治療における可能性を探っています。こうした新たな応用は、市場の範囲と影響力を大幅に拡大すると推定されます。

CAR-T細胞療法市場レポートハイライト

適応症別では、濾胞性リンパ腫（FL）分野が最も速いペースで成長すると予測され、予測期間中のCAGRは43.2%です。

標的抗原に基づくと、CD19/CD22抗原セグメントは、びまん性大細胞型B細胞リンパ腫（DLBCL）や急性リンパ芽球性白血病（ALL）などのB細胞悪性腫瘍の治療において確立された役割により、2024年に6兆2,585億米ドルと評価され、最大の市場シェアを占めました。

世界市場では、北米のCAR-T細胞療法市場が2024年に47.16%の市場シェアを占めました。これは、高度なヘルスケアインフラの存在、多額の研究開発投資、血液悪性腫瘍の高い有病率によるものです。

欧州のCAR-T細胞療法市場は、再発または難治性の血液がんの有病率の上昇に加え、先進治療へのアクセス拡大への注目が高まっていることから、予測期間中に33.2%のCAGRが見込まれています。

世界の主要市場企業の一例としては、Bluebird Bio、Celgene Corporation、Gilead Sciences、Cellectis、Servier Laboratories、Pfizer Inc.、Merck、Amgen、Intellia Therapeutics、Novartis、Caribou Biosciences、Celyad、Bellicum Pharmaceuticals、Noile-Immune Biotech、Nanjing Legend Biotechnology Co.などが挙げられます。

目次

第1章 イントロダクション

  • レポートの説明
    • 研究の目的
    • 市場範囲
  • 前提条件
  • 利害関係者
  • 略語一覧

第2章 エグゼクティブサマリー

  • 市場のハイライト

第3章 調査手法

  • 概要
    • データマイニング
  • データソース
    • 一次情報
    • 二次情報

第4章 CAR-T細胞療法市場の洞察

  • CAR-T細胞療法市場力学
    • 促進要因と機会
      • DLBCLと多発性骨髄腫の新薬の発売も相まって白血病分野で有望な成長
      • 固形腫瘍への応用の可能性
    • 抑制要因と課題
      • 患者の再発
      • 製造と物流の課題
      • 経済モデル/償還/スケーリング
  • PEST分析
  • CAR-T細胞療法開発のタイムライン
  • CAR-T細胞製造の見通し
  • CAR-T細胞の副作用
  • 固形腫瘍を標的とする抗原
  • CAR-Tの臨床試験の情勢
  • 商業情勢（合併と買収、パートナーシップとコラボレーション）
  • CAR-T療法における新たなイノベーション
    • 「既成」CAR-Tまたは同種CAR-T
    • デュアルCAR-Tの開発
    • 非ウイルス転写技術の開発
    • TILとTCR療法の登場
      • TCR（T細胞受容体）
      • TIL（腫瘍浸潤リンパ球）
  • コロナ影響分析
  • カスタマイズ - CAR-T細胞市場

第5章 CAR-T細胞療法市場評価：適応症別

  • イントロダクション
  • DLBCL
  • ALL
  • CLL
  • MM
  • FL
  • 肥満細胞症
  • 骨髄線維症
  • MLLL
  • 胸腺がん
  • 神経膠芽腫
  • AML
  • その他の適応症

第6章 世界のCAR-T細胞療法市場：標的抗原別

  • イントロダクション
  • CD19/CD22
  • BCMA
  • その他

第7章 CAR-T細胞療法市場評価：地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • オーストリア
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第8章 競合情勢

  • 製品の発売と買収は企業に最も採用されている戦略である
  • 製品発売
  • 提携 / 協業 / 合意 / 公開

第9章 企業プロファイル

  • Bluebird Bio
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Celgene Corporation
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Gilead Sciences, Inc.
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Cellectis
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Servier Laboratories
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Pfizer Inc.
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Merck KGaA
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Amgen Inc.
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Intellia Therapeutics
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Novartis International AG
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Caribou Biosciences, Inc
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Celyad
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Bellicum Pharmaceuticals, Inc.
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Noile-Immune Biotech
    • 会社概要
    • 製品ベンチマーク
    • 最近の開発
  • Nanjing Legend Biotechnology Co., Ltd.
    • 会社概要
    • 製品ベンチマーク
    • 最近の開発
  • Johnson & Johnson
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
  • Sangamo Therapeutics, Inc.
    • 会社概要
    • 財務実績
    • 製品ベンチマーク
    • 最近の開発
図表

List of Tables

Table 1 Selected significant catalysts in CAR-T

Table 2 Various antigen targets are investigated for solid tumors

Table 3 Top Developers in CAR T cell clinical trials (September 2019)

Table 4 Catalyst for Small Players

Table 5 Selected deals and partnerships

Table 6 Cost of production (Lentivirus), 2022, (USD Billion)

Table 7 Cost of production (Plasmid), 2022, (USD Billion)

Table 8 Reimbursement amounts for CAR-T therapies per region, 2022, (USD Billion)

Table 9 Global CAR-T Cell Therapy Market, by Indication, 2020-2034, (USD Billion)

Table 10 Global CAR-T Cell Therapy Market, by DLBCL, 2020-2034, (USD Billion)

Table 11 Global CAR-T Cell Therapy Market, by ALL, 2020-2034, (USD Billion)

Table 12 Global CAR-T Cell Therapy Market, by CLL, 2020-2034, (USD Billion)

Table 13 Global CAR-T Cell Therapy Market, by MM, 2020-2034, (USD Billion)

Table 14 Global CAR-T Cell Therapy Market, by FL, 2020-2034, (USD Billion)

Table 15 Global CAR-T Cell Therapy Market, by Mastozytosis, 2020-2034, (USD Billion)

Table 16 Global CAR-T Cell Therapy Market, by Myeloid Fibrosis, 2020-2034, (USD Billion)

Table 17 Global CAR-T Cell Therapy Market, by MLL, 2020-2034, (USD Billion)

Table 18 Global CAR-T Cell Therapy Market, by Thymic Cancer, 2020-2034, (USD Billion)

Table 19 Global CAR-T Cell Therapy Market, by Glioblastoma, 2020-2034, (USD Billion)

Table 20 Global CAR-T Cell Therapy Market, by AML, 2020-2034, (USD Billion)

Table 21 Global CAR-T Cell Therapy Market, by Other Indications, 2020-2034, (USD Billion)

Table 22 Global CAR-T Cell Therapy Market, By Target Antigen, 2015 - 2026 (USD Billion)

  • Table 23 Global CAR-T Cell Therapy Market, by CD19/CD22, by Region, 2020-2034, (USD Billion)
  • Table 24 Global CAR-T Cell Therapy Market, by BCMA, 2020-2034, (USD Billion)
  • Table 25 Global CAR-T Cell Therapy Market, by Others, 2020-2034, (USD Billion)

Table 26 CAR-T Cell Therapy Market Assessment, By Geography, 2020-2034, (USD Billion)

Table 27 North America: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 28 North America: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 29 U.S.: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 30 U.S.: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 31 Canada: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 32 Canada: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 33 Europe: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 34 Europe: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 35 Germany: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 36 Germany: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 37 UK: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 38 UK: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 39 France: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 40 France: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 41 Italy: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 42 Italy: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 43 Spain: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 44 Spain: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 45 Netherlands: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 46 Netherlands: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 47 Austria: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 48 Austria: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 49 Asia Pacific: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 50 Asia Pacific: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 51 China: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 52 China: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 53 India: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 54 India: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 55 Japan: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 56 Japan: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 57 South Korea: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 58 South Korea: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 59 Australia: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 60 Australia: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 61 Latin America: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 62 Latin America: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 63 Brazil: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 64 Brazil: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 65 Mexico: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 66 Mexico: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 67 Middle East & Africa: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 68 Middle East & Africa: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 69 Saudi Arabia: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 70 Saudi Arabia: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

Table 71 UAE: CAR-T Cell Therapy Market, By Indication, 2020-2034, (USD Billion)

Table 72 UAE: CAR-T Cell Therapy Market, By Target Antigen, 2020-2034, (USD Billion)

  • List of Figures
  • Figure 1. Market Highlights
  • Figure 2. Research Methodology: Top Down & Bottom Up Approach
  • Figure 3. Porter's Five Forces
  • Figure 4. CAR-T Timelines
  • Figure 5. CAR-T manufacturing process of Kymriah (Novartis)
  • Figure 6. Market by Indication
  • Figure 7. Market by Target Antigen
目次
Product Code: PM1389

The global CAR-T cell therapy market size is expected to reach USD 188.84 billion by 2034, according to a new study by Polaris Market Research. The report "CAR-T Cell Therapy Market Size, Share, Trends, Industry Analysis Report: By Indication, Target Antigen [CD19/CD22, BCMA (B-Cell Maturation Antigen), and Others], and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Chimeric Antigen Receptor T-cell (CAR-T) therapy represents an advancement in cancer treatment, transforming immuno-oncology. The therapy offers personalized and highly effective treatment options for certain cancers, particularly hematological malignancies, by engineering a patient's T-cells to express synthetic receptors that target specific cancer antigens. The global CAR-T cell therapy market has witnessed exponential growth over the last decade, driven by rapid advancements in biotechnology, increasing approval rates of CAR-T therapies, and rising demand for innovative cancer treatments.

The increasing prevalence of cancer globally, coupled with a growing preference for precision medicine, has fueled demand for advanced treatment modalities such as CAR-T cell therapy. Moreover, supportive regulatory frameworks and rapid approval pathways have accelerated the availability of CAR-T therapies. Government and private investments in research further propel the CAR-T cell therapy market expansion.

The development of next-generation CAR-T therapies, including multi-target CAR-T cells and armored CAR-T cells, is driving the CAR-T cell therapy market growth. Multi-target CAR-T cells are engineered to recognize multiple antigens, addressing issues such as tumor heterogeneity and antigen escape, which limit the efficacy of traditional CAR-T treatments. Armored CAR-T cells are designed to overcome the immunosuppressive tumor microenvironment by secreting cytokines or other molecules to enhance anti-tumor activity.

The application of CAR-T therapy is expanding beyond oncology. Researchers are exploring its potential in treating autoimmune diseases such as lupus and multiple sclerosis and infectious diseases, including HIV. These novel applications are estimated to significantly broaden the market scope and impact.

CAR-T Cell Therapy Market Report Highlights

In terms of indication, the follicular lymphoma (FL) segment is expected to grow at the fastest pace, with a CAGR of 43.2% during the forecast period due to the rising incidence of refractory and high-risk cancer cases.

Based on target antigen, the CD19/CD22 antigen segment, valued at USD 6,258.5 billion in 2024, held the largest market share owing to its established role in treating B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL).

In the global market, the North America CAR-T cell therapy market held a 47.16% market share in 2024 due to the presence of advanced healthcare infrastructure, significant research and development investments, and a high prevalence of hematologic malignancies.

The Europe CAR-T cell therapy market is expected to witness a CAGR of 33.2% during the forecast period due to increased focus on expanding access to advanced therapies, coupled with the rising prevalence of relapsed or refractory hematologic cancers.

A few of the global key market players are Bluebird Bio; Celgene Corporation; Gilead Sciences; Cellectis; Servier Laboratories; Pfizer Inc.; Merck; Amgen; Intellia Therapeutics; Novartis; Caribou Biosciences; Celyad; Bellicum Pharmaceuticals, Inc.; Noile-Immune Biotech; Nanjing Legend Biotechnology Co., Ltd.; Johnson & Johnson; and Sangamo Therapeutics, Inc.

Polaris Market Research has segmented the CAR-T cell therapy market report on the basis of indication, antigen, and region:

By Indication Outlook (Revenue, USD Billion, 2020-2034)

  • DLBCL (Diffuse large B-cell lymphoma)
  • ALL (Acute Lymphoblastic Leukemia)
  • CLL (Chronic Lymphocytic Leukemia)
  • MM (Multiple Myeloma)
  • FL (Follicular Lymphoma)
  • Mastozytosis
  • Myeloid Fibrosis
  • MLL (Mixed Lineage Leukemia)
  • Thymic Cancer
  • Glioblastoma
  • AML (Acute Myeloid Leukemia)
  • Other

By Target Antigen Outlook (Revenue, USD Billion, 2020-2034)

  • CD19/CD22
  • BCMA (B-Cell Maturation Antigen)
  • Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

Chapter 1. Introduction

  • 1.1 Report Description
    • 1.1.1 Objectives of the Study
    • 1.1.2 Market Scope
  • 1.2 Assumptions
  • 1.3 Stakeholders
  • 1.4 List of Abbreviations

Chapter 2. Executive Summary

  • 2.1 Market Highlights

Chapter 3. Research Methodology

  • 3.1 Overview
    • 3.1.1 Data Mining
  • 3.2 Data Sources
    • 3.2.1 Primary Sources
    • 3.2.2 Secondary Sources

Chapter 4. CAR-T Cell Therapy Market Insights

  • 4.1 CAR-T Cell Therapy Market Dynamics
    • 4.1.1 Drivers and Opportunities
      • 4.1.1.1 Promising growth in leukemia segment for DLBCL and Multiple Myeloma coupled with launches
      • 4.1.1.2 Potential applications in solid tumor
    • 4.1.2 Restraints and Challenges
      • 4.1.2.1 Patient Relapse
      • 4.1.2.2 Manufacturing and logistics challenges
      • 4.1.2.3 Economic model/reimbursement/scaling
  • 4.2 Porter's Five Forces Analysis
    • 4.2.1 Bargaining Power of Suppliers (High)
    • 4.2.2 Threats of New Entrants: (High)
    • 4.2.3 Bargaining Power of Buyers (Low)
    • 4.2.4 Threat of Substitute (Low)
    • 4.2.5 Rivalry among existing firms (High)
  • 4.3 PEST Analysis
  • 4.4 Timeline of CAR-T Cell Therapy Development
  • 4.5 CAR-T Cell Manufacturing Outlook
  • 4.6 Side-effects of CAR-T Cell
  • 4.7 Antigens targeting solid tumors
  • 4.8 Clinical trials Landscape for CAR-T
  • 4.9 Commercial Landscape (Mergers & Acquisitions, Partnerships & Collaborations)
  • 4.10 New Innovations in CAR-T therapies
    • 4.10.1 "Off-the-shelf" CAR-T or allogenic CAR-T
    • 4.10.2 Development of Dual CAR-T
    • 4.10.3 Development of Non-viral transcription technologies
    • 4.10.4 The advent of TIL as well as TC R therapies
      • 4.10.4.1 TCR (T-cell receptor)
      • 4.10.4.2 TIL (Tumor-Infiltrating Lymphocytes)
  • 4.11 CAR-T Cell Therapy Market - Covid Impact Analysis
  • 4.12 Customization - CAR-T Cell Market

Chapter 5. CAR-T Cell Therapy Market Assessment by Indication

  • 5.1 Introduction
  • 5.2 DLBCL
  • 5.3 ALL
  • 5.4 CLL
  • 5.5 MM
  • 5.6 FL
  • 5.7 Mastozytosis
  • 5.8 Myeloid Fibrosis
  • 5.9 MLL
  • 5.10 Thymic Cancer
  • 5.11 Glioblastoma
  • 5.12 AML
  • 5.13 Other Indications

Chapter 6. Global CAR-T Cell Therapy Market, by Target Antigen

  • 6.1 Introduction
  • 6.2 CD19/CD22
  • 6.3 BCMA
  • 6.4 Others

Chapter 7. CAR-T Cell Therapy Market Assessment by Geography

  • 7.1 Introduction
  • 7.2 CAR-T Cell Therapy Market - North America
    • 7.2.1 CAR-T Cell Therapy Market - U.S.
    • 7.2.2 CAR-T Cell Therapy Market - Canada
  • 7.3 CAR-T Cell Therapy Market - Europe
    • 7.3.1 CAR-T Cell Therapy Market - Germany
    • 7.3.2 CAR-T Cell Therapy Market - UK
    • 7.3.3 CAR-T Cell Therapy Market - France
    • 7.3.4 CAR-T Cell Therapy Market - Italy
    • 7.3.5 CAR-T Cell Therapy Market - Spain
    • 7.3.6 CAR-T Cell Therapy Market - Netherlands
    • 7.3.7 CAR-T Cell Therapy Market - Austria
  • 7.4 CAR-T Cell Therapy Market - Asia Pacific
    • 7.4.1 CAR-T Cell Therapy Market - China
    • 7.4.2 CAR-T Cell Therapy Market - India
    • 7.4.3 CAR-T Cell Therapy Market - Japan
    • 7.4.4 CAR-T Cell Therapy Market - South Korea
    • 7.4.5 CAR-T Cell Therapy Market - Australia
  • 7.5 CAR-T Cell Therapy Market - Latin America
    • 7.5.1 CAR-T Cell Therapy Market - Brazil
    • 7.5.2 CAR-T Cell Therapy Market - Mexico
  • 7.6 CAR-T Cell Therapy Market - Middle East & Africa
    • 7.6.1 CAR-T Cell Therapy Market - Saudi Arabia
    • 7.6.2 CAR-T Cell Therapy Market - UAE

Chapter 8. Competitive Landscape

  • 8.1 Product Launch and Acquisition Are the Best Adopted Strategy by the Companies
  • 8.2 Product Launch
  • 8.3 Partnerships/Collaborations/Agreements/Exhibitions

Chapter 9. Company Profiles

  • 9.1 Bluebird Bio
    • 9.1.1 Company Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Benchmarking
    • 9.1.4 Recent Development
  • 9.2 Celgene Corporation
    • 9.2.1 Company Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Benchmarking
    • 9.2.4 Recent Development
  • 9.3 Gilead Sciences, Inc.
    • 9.3.1 Company Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Benchmarking
    • 9.3.4 Recent Development
  • 9.4 Cellectis
    • 9.4.1 Company Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Benchmarking
    • 9.4.4 Recent Development
  • 9.5 Servier Laboratories
    • 9.5.1 Company Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Benchmarking
    • 9.5.4 Recent Development
  • 9.6 Pfizer Inc.
    • 9.6.1 Company Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Benchmarking
    • 9.6.4 Recent Development
  • 9.7 Merck KGaA
    • 9.7.1 Company Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Benchmarking
    • 9.7.4 Recent Development
  • 9.8 Amgen Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Benchmarking
    • 9.8.4 Recent Development
  • 9.9 Intellia Therapeutics
    • 9.9.1 Company Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Benchmarking
    • 9.9.4 Recent Development
  • 9.10 Novartis International AG
    • 9.10.1 Company Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Benchmarking
    • 9.10.4 Recent Development
  • 9.11 Caribou Biosciences, Inc
    • 9.11.1 Company Overview
    • 9.11.2 Financial Performance
    • 9.11.3 Product Benchmarking
    • 9.11.4 Recent Development
  • 9.12 Celyad
    • 9.12.1 Company Overview
    • 9.12.2 Financial Performance
    • 9.12.3 Product Benchmarking
    • 9.12.4 Recent Development
  • 9.13 Bellicum Pharmaceuticals, Inc.
    • 9.13.1 Company Overview
    • 9.13.2 Financial Performance
    • 9.13.3 Product Benchmarking
    • 9.13.4 Recent Development
  • 9.14 Noile-Immune Biotech
    • 9.14.1 Company Overview
    • 9.14.2 Product Benchmarking
    • 9.14.3 Recent Development
  • 9.15 Nanjing Legend Biotechnology Co., Ltd.
    • 9.15.1 Company Overview
    • 9.15.2 Product Benchmarking
    • 9.15.3 Recent Development
  • 9.16 Johnson & Johnson
    • 9.16.1 Company Overview
    • 9.16.2 Financial Performance
    • 9.16.3 Product Benchmarking
    • 9.16.4 Recent Development
  • 9.17 Sangamo Therapeutics, Inc.
    • 9.17.1 Company Overview
    • 9.17.2 Financial Performance
    • 9.17.3 Product Benchmarking
    • 9.17.4 Recent Development